<abstract xmlns="http://www.w3.org/1999/xhtml">Objective. The aim of the present study was to investigate the effect of hypoxia on the expression of genes encoding insulin-like growth factors (IGF1 and IGF2), their receptor (IGF1R), binding protein-4 (IGFBP4), and stanniocalcin 2 (STC2) in U87 glioma cells in relation to inhibition of endoplasmic reticulum stress signaling mediated by IRE1 (inositol requiring enzyme 1) for evaluation of their possible significance in the control of tumor growth. Methods. The expression of IGF1, IGF2, IGF1R, IGFBP4, and STC2 genes in U87 glioma cells transfected by empty vector pcDNA3.1 (control) and cells without IRE1 signaling enzyme function (transfected by dnIRE1) upon hypoxia was studied by qPCR. Results. The expression of IGF1 and IGF2 genes is down-regulated in glioma cells without IRE1 signaling enzyme function in comparison with the control cells. At the same time, the expression of IGF1R, IGFBP4, and STC2 genes was up-regulated in glioma cells upon inhibition of IRE1, with more significant changes for IGFBP4 and STC2 genes. We also showed that hypoxia does not change significantly the expression of IGF1, IGF2, and IGF1R genes but up-regulated IGFBP4 and STC2 genes expression in control glioma cells. Moreover, the inhibition of both enzymatic activities (kinase and endoribonuclease) of IRE1 in glioma cells does not change significantly the effect of hypoxia on the expression of IGF1, IGF1R, and IGFBP4 genes but introduces sensitivity of IGF2 gene to hypoxic condition. Thus, the expression of IGF2 gene is resistant to hypoxia only in control glioma cells and significantly down-regulated in cells without functional activity of IRE1 signaling enzyme, which is central mediator of the unfolded protein response and an important component of the tumor growth as well as metabolic diseases. Conclusions. Results of this study demonstrate that the expression of IGF1 and IGF1R genes is resistant to hypoxic condition both in control U87 glioma cells and cells without IRE1 signaling enzyme function. However, hypoxia significantly up-regulates the expression of IGFBP4 gene independently on the inhibition of IRE1 enzyme. These data show that proteins encoded by these genes are resistant to hypoxia except IGFBP4 and participate in the regulation of metabolic and proliferative processes through IRE1 signaling.</abstract>

Department of Molecular Biology, Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv, Ukraine

Department of Pediatrics, National Bohomolets Medical University, Kyiv, Ukraine

Effect of hypoxia on the expression of genes encoding insulin-like growth factors and some related proteins in U87 glioma cells without IRE1 function

<abstract xmlns="http://www.w3.org/1999/xhtml">Objective. Interleukin-35 (IL-35), an interleukin-12 (IL-12) cytokine family member, is shown to be a potent immunosuppressive and anti-inflammatory cytokine. Inducible regulatory T cells (Tregs) produce IL-35 that mediates the immune inhibitory function of Tregs. Growing evidence revealed that upregulation of IL-35 expression may play a critical role in the prevention of autoimmune diseases in various experimental autoimmunity models and vice versa. Hashimoto’s thyroiditis (HT) is considered to be a Treg cell-related autoimmune disease with loss of self-tolerance. Methods. One hundred-twenty eight subjects, newly diagnosed hypothyroid HT patients [56 overt (Group 1), 72 subclinical hypothyroid (Group 2)] and 38 healthy controls (Group 3) were enrolled in the study. The levels of serum IL-35 were determined by enzyme-linked immunosorbent assay (ELISA). Results. Serum IL-35 levels were lower in the HT group when compared with subclinical HT group [304.5 (834.6) pg/ml vs. 636.1 (1542.0) pg/ml, p=0.004] and control cases [304.5 (834.6) pg/ml vs. 1064.7 (2526.8) pg/ml, p&lt;0.001]. Serum IL-35 levels were inversely associated with thyroid stimulating hormone (TSH; rs=-0.396, p&lt;0.001) and anti-thyroid peroxidase antibodies (TPOAb; rs=-0.571, p&lt;0.001) in whole group. Serum IL-35 were negatively associated with TSH (rs=-0.264, p=0.003) and TPOAb (rs=-0.735, p&lt;0.001) in patients with Hashimoto’s thyroiditis (Group 1 + Group 2). Conclusion. The results suggest that IL-35 may play a role in the pathogenesis of HT.</abstract>

Department of Internal Medicine, Dr. A. Y. Ankara Oncology Training and Research Hospital, Ankara, Turkey

Department of Internal Medicine, Turgut Ozal University, School of Medicine, Ankara, Turkey

Department of Endocrinology, Turgut Ozal University, School of Medicine, Ankara, Turkey

Department of Endocrinology, Dr. A. Y. Ankara Oncology Training and Research Hospital, Ankara, Turkey

Role of interlekin-35 as a biomarker in patients with newly diagnosed Hashimoto’s thyroiditis

<abstract xmlns="http://www.w3.org/1999/xhtml">Gestational diabetes mellitus (GDM) is defined as a glucose intolerance that occurs for the first time or it is first identified during pregnancy. The GDM etiology is multifactorial. It has not completely been established yet and several known risk factors may contribute to its onset. To date, there are no shared guidelines on the management and follow-up, especially regarding the low-income countries. In this paper, we describe the state of art about epidemiology, physiopathology, diagnosis, and management of GDM. Moreover, we focus on the current state in low income countries trying to outline basis for further research.</abstract>

Unit of Neonatology and Intensive Care, General Hospital, University of Bari, Bari, Italy

Research Section, Doctors with Africa CUAMM, Padova, Italy

Gynaecology and Obstetrics Unit, General Hospital, University of Bari, Bari, Italy

Research Section, Doctors with Africa CUAMM, Beira, Mozambique

Gestational diabetes: An overview with attention for developing countries

<abstract xmlns="http://www.w3.org/1999/xhtml">The present knowledge, regarding the neuronal growth and neurite extension, includes neuropeptide action in the central nervous system. Research reports have brought much information about the multiple intracellular signaling pathways of neuropeptides. However, regardless of the differences in the local responses elicited by neuropeptides, there exist certain functional similarities in the effects of neuropeptides, mediated by their receptors. In the present review, data of the relevant studies, focused on G protein-coupled receptors activated by neuropeptides, are summarized. Particularly, receptors that activate phosphatidylinositol-calcium system and protein kinase C pathways, resulting in the reorganization of the neuronal cytoskeleton and changes in the neuronal morphology, are discussed. Based on our data received, we are showing that oxytocin increases the gene expression of GTPase cell division cycle protein 42 (Cdc42), implicated in many aspects of the neuronal growth and morphology. We are also paying a special attention to neurite extension and retraction in the context of neuropeptide regulation.</abstract>

Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia

Department of Normal and Pathological Physiology, Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia

Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia;

Institute of Physiology, Comenius University, Faculty of Medicine, Bratislava, Slovakia

Mechanisms involved in the regulation of neuropeptide-mediated neurite outgrowth: a minireview

<abstract xmlns="http://www.w3.org/1999/xhtml">Micro RNAs (miRNAs) are small regulatory molecules of increasing biologists’ interest. miRNAs, unlikely mRNA, do not encode proteins. It is a class of small double stranded RNA molecules that via their seed sequence interact with mRNA and inhibit its expression. It has been estimated that 30% of human gene expression is regulated by miRNAs. One miRNA usually targets several mRNAs and one mRNA can be regulated by several miRNAs. miRNA biogenesis is realized by key enzymes, Drosha and Dicer. miRNA/mRNA interaction depends on binding to RNA-induced silencing complex. Today, complete commercially available methodical proposals for miRNA investigation are available. There are techniques allowing the identification of new miRNAs and new miRNA targets, validation of predicted targets, measurement of miRNAs and their precursor levels, and validation of physiological role of miRNAs under in vitro and in vivo conditions. miRNAs have been shown to influence gene expression in several endocrine glands, including pancreas, ovary, testes, hypothalamus, and pituitary.</abstract>

Progress in micro RNA focused research in endocrinology

<abstract xmlns="http://www.w3.org/1999/xhtml">Micro RNAs (miRNAs) represent a newly discovered class of regulatory molecules in the human body. miRNA is a short double stranded RNA sequence interfering with mRNA, causing in most cases, inhibition of translation. Synthesis of miRNAs shows an increasing developmental pattern and postnatally miRNAs are synthesized in all cells possessing transcriptional machinery. miRNAs usually target several mRNAs and therefore conclusive evidences proving their functions are not always ease to be acquired. In spite of this difficulty, functions of miRNAs were firmly established in the development, the cardiovascular and neural diseases, and cancer. Many miRNAs have been reported to be associated with physiological state of cells and/or tissues. This finding becomes fundamental, especially when consider that these miRNAs can be released from cell into intracellular space or circulation. Correlation between miRNA production in tissues and its contribution to multisource miRNA pool in the circulation is in a focus of biomarker-oriented researchers. Recently, circulating miRNAs have been suggested to be applicable as biomarkers in several types of cancer, cardiovascular injury, and diabetes. Role of miRNAs in the organism intercellular signaling is still under the broad investigation. Several miRNA mimics, intended for treatment of disease, are being currently tested in the clinical trials.</abstract>

Micro RNAs: an arguable appraisal in medicine

AHEAD OF PRINT

Volume 58 (2024): Issue 1 (January 2024)

Volume 57 (2023): Issue 1 (January 2023)

Volume 56 (2022): Issue 4 (October 2022)

Volume 56 (2022): Issue 3 (July 2022)

Volume 56 (2022): Issue 2 (April 2022)

Volume 56 (2022): Issue 1 (January 2022)

Volume 55 (2021): Issue 4 (October 2021)

Volume 55 (2021): Issue 3 (July 2021)

Volume 55 (2021): Issue 2 (April 2021)

Volume 55 (2021): Issue 1 (January 2021)

Volume 54 (2020): Issue 4 (October 2020)

Volume 54 (2020): Issue 3 (July 2020)

Volume 54 (2020): Issue 2 (April 2020)

Volume 54 (2020): Issue 1 (January 2020)

Volume 53 (2019): Issue 4 (October 2019)

Volume 53 (2019): Issue 3 (July 2019)

Volume 53 (2019): Issue 2 (April 2019)

Volume 53 (2019): Issue 1 (January 2019)

Volume 52 (2018): Issue 4 (October 2018)

Volume 52 (2018): Issue 3 (July 2018)

Volume 52 (2018): Issue 2 (April 2018)

Volume 52 (2018): Issue 1 (January 2018)

Volume 51 (2017): Issue 4 (October 2017)

Volume 51 (2017): Issue 3 (July 2017)

Volume 51 (2017): Issue 2 (April 2017)

Volume 51 (2017): Issue 1 (January 2017)

Volume 50 (2016): Issue 4 (October 2016)

Volume 50 (2016): Issue 3 (July 2016)

Volume 50 (2016): Issue 2 (April 2016)

Volume 50 (2016): Issue 1 (January 2016)

Endocrine Regulations

 Endocrine Regulations (from 1967 to 1990 as Endocrinologia Experimentalis), an open access, peer reviewed international journal, welcomes the submission of original research papers and review articles from traditionally recognized fields of experimental and clinical endocrinology, including neuroendocrinology, thyroid and adrenal gland research, metabolism and diabetes, reproduction, and genetic endocrinology. Basic and pathophysiological studies using animal models, and research studies at cellular and molecular level are also considered, as well as human sample studies, where this is the experimental model of choice. Clinical case reports are also welcome.   Why subscribe and read    source of high quality basic and clinical research (original research papers, review articles, case reports, short communications) related to interdisciplinary endocrinology fields,   peer-reviewed by international experts,   available in electronic format,   free of charge access (open access) for readers    Why submit   Endocrine Regulations is an open access journal that publishes papers, which are accessible to international audience and indexed by abstracting and full-text databases including PubMed, Scopus, Embase, etc.The manuscripts are submitted via Editorial Manager system, which reduces the editorial processing and reviewing time of manuscripts, and shortening the overall publication process.       Archiving   Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.   Plagiarism Policy   The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. 